GSK199是口服活性强、可逆且选择性高的PAD4抑制剂，不含钙离子时IC₅₀为200nM，通过调控组蛋白瓜氨酸化和中性粒细胞胞外陷阱形成，可用于类风湿性关节炎、自身免疫、心血管及肿瘤疾病的研究。

[1] Pasquero S, Gugliesi F, Griffante G, Dell'Oste V, Biolatti M, Albano C, Bajetto G, Delbue S, Signorini L, Dolci M, Landolfo S, De Andrea M. Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2. Antiviral Res. 2022 Apr;200:105278. doi: 10.1016/j.antiviral.2022.105278. Epub 2022 Mar 11. PMID: 35288208; PMCID: PMC8915624.[2]Hallur G, et al. LC-ESI-MS/MS Determination of GSK-199, A Novel Reversible PAD4 Inhibitor in Mice Plasma and its Application to a Pharmacokinetic Study in Mice. Pharm Anal Chem. 2017, 3(124): 40-1.